TB research initiated by EDCTP member countries
Clinical research activities initiated by EDCTP member countries (or Participating States) within the scope of the EDCTP programme can be considered to be part of the programme. These projects, called PSIAs (Participating States’ Initiated Activities), are supported with national funding and independently executed by European and African member countries. The PSIAs are important as they directly contribute to achieving the EDCTP objectives and are incorporated in the EDCTP work plans.
Some of the PSIAs are multi-country activities, in which more than two Participating States collaborate. One example is the collaboration of three European countries – Denmark, Netherlands and Norway – who initiated a phase II trial to evaluate one of the leading TB vaccine candidates (H56:IC31) in Tanzanian and South African adolescents. The project started in 2016 and brings together Norway (GLOBVAC, University of Bergen and Oslo University Hospital), Denmark (Statens Serum Institut, University of Copenhagen and GSK Europe), Netherlands (Leiden University Medical Center), South Africa (Aeras South Africa, The Aurum Institute, South African TB Vaccine Initiative (University of Cape Town)), Tanzania (National Institute for Medical Research, Mwanza), and the United States (Aeras).